We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. David Portman is founder and CEO of Sermonix Pharmaceuticals where he leads the lasofoxifene development program for the treatment of advanced breast cancer. He was the Founder and is Director Emeritus of the Columbus Center for Women's Health Research as well as Adjunct Instructor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine. Dr. Portman has conducted over 140 clinical studies in Selective Estrogen Receptor Modulators (SERMs), including acting as principal investigator in Pfizer’s non-oncology osteoporosis and vulvovaginal atrophy development programs for lasofoxifene. He has published dozens of articles in numerous peer-reviewed medical journals including the American Journal of Obstetrics and Gynecology, Menopause, Journal of Sexual Medicine, Obstetrics and Gynecology, and Contraception.
This speaker's sessions: